Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
LHCGR
REST API REST API
Homo sapiens
LHCGR is differentially expressed in 118 experiments: 83 organism parts: dorsal root ganglion, lung, ... (81 more);, 68 disease states: normal, healthy, ... (66 more);, 29 cell types 48 cell lines 8 compound treatments and 56 other conditions.
Synonyms LGR2, LCGR, ULG5, LHR, HHG
Orthologs LHCGR (Bos taurus)   Lhcgr (Rattus norvegicus)   Lhcgr (Mus musculus)   lhcgr (Danio rerio)   F1NGD6_CHICK (Gallus gallus)   Fsh (Drosophila melanogaster)   LHCGR (Xenopus laevis)   Q95MF7_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, endoplasmic reticulum, peptide receptor activity, G-protein coupled, cytoplasm, G-protein signaling, coupled to cAMP nucleotide second messenger, extracellular space, activation of phospholipase C activity by G-protein coupled receptor protein signaling pathway coupled to IP3 second messenger, lysosome, male genitalia development, hormone-mediated signaling pathway, G-protein coupled receptor protein signaling pathway, spermatogenesis, male gonad development, female gonad development, signal transducer activity, identical protein binding, integral to plasma membrane, nucleus, receptor activity, endosome, response to drug, protein homodimerization activity, integral to membrane, protein targeting to lysosome, central nervous system development, activation of adenylate cyclase activity, peptide hormone binding, positive regulation of release of sequestered calcium ion into cytosol, luteinizing hormone receptor activity, development of secondary male sexual characteristics, ATPase binding, uterus development, G-protein signaling, coupled to cyclic nucleotide second messenger, ovulation cycle process, intrinsic to external side of plasma membrane, receptor complex, ovarian follicle development, positive regulation of calcium ion transport into cytosol, positive regulation of calcium-mediated signaling, regulation of steroid biosynthetic process, luteinizing hormone signaling pathway, positive regulation of hormone biosynthetic process, arachidonic acid secretion, seminiferous tubule development, ovum-producing ovary development, choriogonadotropin hormone receptor activity, regulation of steroid hormone biosynthetic process
InterPro Term GPCR_Rhodpsn_supfam, 7TM_GPCR_Rhodpsn, TSH_rcpt, Gphrmn_rcpt, LSH_rcpt
Gene-Disease Assocation PRECOCIOUS PUBERTY, MALE-LIMITED, LEYDIG CELL HYPOPLASIA, TYPE I
UniProt Accession P22888, Q53S49, Q4ZFZ4, E7ENI1, E7EQB5, E7ESK4, E9PDH1, E3W981
Search EB-eye ENSG00000138039
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-MTAB-37, E-GEOD-5823, E-GEOD-2450, E-GEOD-19480, E-MEXP-1014, ... (6 experiments)

Factor Value U/D Experiments
SUM149PT
1
E-MTAB-62
m-o7e cell line
1
E-MTAB-62
k562
1
E-MTAB-62
MCIXC
1
E-MTAB-37
HuNS1
1
E-MTAB-37
NCIH1666
1
E-MTAB-37
42 more value(s).


Cell type

studied in E-AFMX-5, E-GEOD-18811, E-MTAB-25, E-GEOD-21668, E-GEOD-20033, ... (17 experiments)

Factor Value U/D Experiments
whole blood
1
E-GEOD-3026
hematopoietic progenitor cells
1
E-MEXP-70
1
1
E-TABM-145
neutrophil
1
E-GEOD-12662
CD326negCD56+ cell
1
E-GEOD-21668
plasma cell
1
E-MEXP-2360
23 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-19743, E-GEOD-6872, E-GEOD-5377, E-GEOD-2466, ... (21 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
1
E-MTAB-62
cancerous
1
E-TABM-15
testicular seminoma
1
E-GEOD-8607
tumor
1
E-GEOD-19188
liver carcinoma
1
E-MTAB-37
osteosarcoma
1
E-MTAB-37
62 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-1923, E-GEOD-3284, E-GEOD-412, E-MEXP-941 ... (5 experiments)

Factor Value U/D Experiments
none
1
2
101
E-GEOD-412, E-GEOD-1615, E-GEOD-1923
platelet-derived growth factor
1
E-GEOD-1923
control
31
1
E-GEOD-3284
valproic acid
1
E-GEOD-1615
glucose
1
E-MEXP-941
bacterial endotoxin
1
1
E-GEOD-3284
2 more value(s).


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
adrenal gland; kidney
1
E-GEOD-5851


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Date of sample preparation and hybridisation
studied in E-GEOD-22541

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-6236, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genotype
studied in E-GEOD-2466, E-GEOD-22593

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-MEXP-1446

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-GEOD-1432, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (20 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108

Injury
studied in E-GEOD-19743

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-GEOD-1801, E-TABM-84

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-MEXP-70

Sex
studied in E-GEOD-2466

Survival time
studied in E-GEOD-3494

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 1.151 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM